Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoreactive T lymphocytes from type 1 diabetic patients

Clinical Immunology

Volumn 154, Issue 1, 2014, Pages 72-83

  Segovia Gamboa, Norma ^a   Rodríguez Arellano, Martha Eunice ^b   Rangel Cruz, Rafael ^b   Sánchez Díaz, Moisés ^b   Ramírez Reyes, Julio César ^b   Faradji, Raquel ^c   González Domínguez, Érika ^a   Sánchez Torres, Carmen ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b HOSPITAL REGIONAL LIC ADOLFO LÓPEZ MATEOS   (Mexico)

^c Medical Services   (Mexico)

Author keywords

Dendritic cells; Tolerance; ; Type 1 diabetes mellitus;

Indexed keywords

GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA1;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; PANCREAS ISLET; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; YOUNG ADULT;

DENDRITIC CELLS; EFFECTOR/MEMORY CD4+ T LYMPHOCYTES;; TOLERANCE;; TYPE 1 DIABETES MELLITUS;;

ADOLESCENT; ADULT; AUTOANTIGENS; BIOLOGICAL ASSAY; CELL PROLIFERATION; CELLS, CULTURED; CHILD; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; FEMALE; FLOW CYTOMETRY; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNE TOLERANCE; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 84904254796     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.06.009     Document Type: Article

References (50)

1. Eisenbarth G.S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 1986, 314:1360-1368.
2. Willcox A., Richardson S.J., Bone A.J., Foulis A.K., Morgan N.G. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol. 2009, 155:173-181.
3. Richardson S.J., Willcox A., Bone A.J., Morgan N.G., Foulis A.K. Immunopathology of the human pancreas in type-1 diabetes. Semin. Immunopathol. 2011, 33:9-21.
4. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation?. Diabetes 1994, 43:613-621.
5. Berman M.A., Sandborg C.I., Wang Z., Imfeld K.L., Zaldivar F., Dadufalza V., Buckingham B.A. Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J. Immunol. 1996, 157:4690-4696.
6. Kuriya G., Uchida T., Akazawa S., Kobayashi M., Nakamura K., Satoh T., Horie I., Kawasaki E., Yamasaki H., Yu L., Iwakura Y., Sasaki H., Nagayama Y., Kawakami A., Abiru N. Double deficiency in IL-17 and IFN-γ signalling significantly suppresses the development of diabetes in the NOD mouse. Diabetologia 2013, 56:1773-1780.
7. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman N., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
8. Fousteri G., Dave A., Bot A., Juntti T., Omid S., von Herrath M. Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia 2010, 53:1958-1970.
9. Merad M., Sathe P., Helft J., Miller J., Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 2013, 31:563-604.
10. Luckashenak N., Schroeder S., Endt K., Schmidt D., Mahnke K., Bachmann M.F., Marconi P., Deeg C.A., Brocker T. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 2008, 28:521-532.
11. Mueller D.L. Mechanisms maintaining peripheral tolerance. Nat. Immunol. 2010, 11:21-27.
12. Gordon J.R., Ma Y., Churchman L., Gordon S.A., Dawicki W. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front. Immunol. 2014, 5:7.
13. Naranjo-Gómez M., Raïch-Regué D., Oñate C., Grau-López L., Ramo-Tello C., Pujol-Borrell R., Martínez-Cáceres E., Borràs F.E. Comparative study of clinical grade human tolerogenic dendritic cells. J. Transl. Med. 2011, 9:89.
14. Sato K., Yamashita N., Baba M., et al. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 2003, 101:3581-3589.
15. Torres-Aguilar H., Aguilar-Ruiz S.R., González-Pérez G., Munguía R., Bajaña S., Meraz-Ríos M.A., Sánchez-Torres C. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J. Immunol. 2010, 184:1765-1775.
16. Sabado R.L., Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2010, 2:37-56.
17. Taner T., Hackstein H., Wang Z., Morelli A.E., Thomson A.W. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am. J. Transplant. 2005, 5:228-236.
18. Clare-Salzler M.J., Brooks J., Chai A., Van Herle K., Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J. Clin. Invest. 1992, 90:741-748.
19. Tai N., Yasuda H., Xiang Y., Zhang L., Rodriguez-Pinto D., Yokono K., Sherwin R., Wong F.S., Nagata M., Wen L. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin. Immunol. 2011, 139:336-349.
20. Machen J., Harnaha J., Lakomy R., Styche A., Trucco M., Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 2004, 173:4331-4341.
21. Feili-Hariri M., Falkner D.H., Morel P.A. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur. J. Immunol. 2002, 32:2021-2030.
22. Papaccio G., Nicoletti F., Pisanti F.A., Bendtzen K., Galdieri M. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. Endocrinology 2000, 141:1500-1505.
23. Haase C., Yu L., Eisenbarth G., Markholst H. Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells. Clin. Exp. Immunol. 2010, 160:331-339.
24. Giannoukakis N., Phillips B., Finegold D., Harnaha J., Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011, 34:2026-2032.
25. Ranjeny T., Street S., Ramnoruth N., Pahau H., Law S., Brunck M., Hyde C., O'Sullivan B.J., Capini C., Tran A., Ng J., Sanjoy P. Feasibility, safety and clinical effects of a single intradermal administration of autologous tolerising dendritic cells exposed to citrullinated peptides in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. 2011, 63(Suppl. 10):2430.
26. Torres-Aguilar H., Sanchez-Torres C., Blank M., Shoenfeld Y. IL-10/TGF-β-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals. J. Clin. Immunol. 2010, 30:659-668.
27. Harry R.A., Anderson A.E., Isaacs J.D., Hilkens C.M.U. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69:2042-2050.
28. Raïch-Regué D., Grau-López L., Naranjo-Gómez M., Ramo-Tello C., Pujol-Borrell R., Martínez-Cáceres E., Borràs F.E. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur. J. Immunol. 2012, 42:771-782.
29. Volchenkov R., Brun J.G., Jonsson R., Appel S. In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome. Arthritis Res. Ther. 2013, 15:R114.
30. Lee J.H., Kim T.H., Park H.E., Lee E.G., Jung N.C., Song J.Y., Seo H.G., Seung K.B., Chang K., Lim D.S. Myosin-primed tolerogenic dendritic cells ameliorate experimental autoimmune myocarditis. Cardiovasc. Res. 2014, 101:203-210.
31. Macedo C., Turquist H., Metes D., Thomson A.W. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant. Res. 2012, 1:16.
32. Schwartz R.H. T cell anergy. Annu. Rev. Immunol. 2003, 21:305-334.
33. Heisel O., Keown P. Alterations in transcription factor binding at the IL-2 promoter region in anergized human CD4+ T lymphocytes. Transplantation 2001, 72:1416-1422.
34. Kubsch S., Graulich E., Knop J., Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur. J. Immunol. 2003, 33:1988-1997.
35. Groux H., Bigler M., de Vries J.E., Roncarolo M.G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med. 1996, 184:19-29.
36. Berger T.G., Schulze-Koops H., Schafer M., Muller E., Lutz M.B. Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro. PLoS ONE 2009, 4:e6645.
37. Roncarolo M.G., Gregori S., Battaglia M., Bacchetta R., Fleischhauer K., Levings M.K. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006, 212:28-50.
38. Cretney E., Kallies A., Nutt S.L. Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol. 2013, 34:74-80.
39. DiPaolo R.J., Brinster C., Davidson T.S., Andersson J., Glass D., Shevach E.M. Autoantigen-specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J. Immunol. 2007, 179:4685-4693.
40. + T helper cells. J. Exp. Med. 2002, 196:255-260.
41. Anderson A.E., Sayers B.L., Haniffa M.A., Swan D.J., Diboll J., Wang X.N., Isaacs J.D., Hilkens C.M. Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. J. Leucok. Biol. 2008, 84:124-133.
42. Yamazaki S., Steinman R.M. Dendritic cells as controllers of antigen-specific Foxp3+ regulatory T cells. J. Dermatol. Sci. 2009, 54:69-75.
43. Gately M.K., Desai B.B., Wolitzky A.G., Quinn P.M., Dwyer C.M., Podlaski F.J., Familletti P.C., Sinigaglia F., Chizonnite R., Gubler U., Stern A.S. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 1991, 147:874-882.
44. + T cell clonal expansion. J. Immunol. 2002, 168:1682-1689.
45. Obst R., van Santen H.M., Mathis D., Benoist C. Antigen persistence is required throughout the expansion phase of a CD4+ T cell response. J. Exp. Med. 2005, 201:1555-1565.
46. Skarsvik S., Tiittanen M., Lindström A., Casas R., Ludvigsson J., Vaarala O. Poor in vitro maturation and pro-inflammatory cytokine response of dendritic cells in children at genetic risk of type 1 diabetes. Scand. J. Immunol. 2004, 60:647-652.
47. Glisic-Milosavljevic S., Wang T., Koppen M., Kramer J., Ehlenbach S., Waukau J., Jailwala P., Jana S., Alemzadeh R., Ghosh S. Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes. Clin. Exp. Immunol. 2007, 150:75-82.
48. Palmer J.P. C-peptide in the natural history of type 1 diabetes. Diabetes Metab. Res. Rev. 2009, 25:325-328.
49. Han X.Q., Gong Z.J., Xu S.Q., Li X., Wang L.K., Wu S.M., Wu J.H., Yang H.F. Advanced glycation end products promote differentiation of CD4(+) T helper cells toward pro-inflammatory response. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2014, 34:10-17.
50. Chiarelli F., de Martino M., Mezzetti A., Catino M., Morgese G., Cuccurullo F., Verrotti A. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J. Pediatr. 1999, 134:486-491.